Drug Database
ME

measles (Tresivac)

✓ Approved

Serum Institute of India Pvt. Ltd. · Vaccine · Vaccine

What is measles?

measles is a vaccine developed by Serum Institute of India Pvt. Ltd.. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesTresivac
CompanySerum Institute of India Pvt. Ltd.
Drug ClassVaccine
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Serum Institute of India Pvt. Ltd.

Therapeutic Indications

measles is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsMeasles✓ Approved

Related Research Articles

PubMedWorld journal of pediatrics : WJP2026-10-16

Associations between parental generative artificial intelligence health-advice use and child vaccination uptake in Japan: an exploratory cross-sectional study.

Imanishi Yousuke Y, Iorini Maria M, Jwa Sinchul S, Sakamoto Masahiko M et al.

Parents increasingly use generative artificial intelligence (AI) for health information, but evidence on parental AI use and childhood vaccination is limited. We examined exploratory associations between regular parental AI health-advice use and childhood vaccination in Japan. This cross-sectional study analyzed 2025 nationwide survey data from children aged 1 to 17 years and parents, with a linked 2023-2025 sub-analysis. The exposure was regular parental use of generative AI for health advice at least a few times per month. Outcomes were age-appropriate measles-rubella (MR) vaccination and any mumps, influenza, or coronavirus disease 2019 (COVID-19) vaccination. Modified Poisson regression estimated adjusted prevalence ratios (aPRs) and 95% confidence interval (95% CI) with parent-level clustering and covariates. Among 8282 children and 5170 parents, 1278 (15.4%) had regular AI health-advice users as parents. AI use was not associated with age-appropriate MR vaccination (aPR 1.02; 95% CI 0.97-1.09), but was associated with three vaccines. The adjusted rates were 76.6 versus 72.7% (aPR 1.05, 95% CI 1.01-1.10) for mumps, 56.7% versus 49.0% (aPR 1.16, 95% CI 1.08-1.24) for influenza, 40.6% versus 30.9% (aPR 1.31, 95% CI 1.19-1.45) for COVID-19. The COVID-19 association was strongest among parents younger than 30 years (aPR 2.58; 95% CI 1.90-3.50; P for interaction < 0.001). In the linked sub-analysis, these associations persisted after adjustment for an available 2023 household-level prior vaccination marker and attitudes. Regular parental use of generative AI for health advice was associated with mumps, influenza, and COVID-19 vaccination, but not with age-appropriate MR vaccination. These exploratory, cross-sectional findings are observational associations. They may reflect digital health engagement, health information seeking, socioeconomic differences, or favorable attitudes, rather than vaccine-specific AI advice.

PMID 42881346
Read full article →
PubMedNature communications2026-10-16

Effectiveness of the oral rotavirus vaccine ROTASIIL among children hospitalized with acute gastroenteritis in India.

Chaudhary Varsha Sudhir VS, Machathi Anupama A, Kharat Namrata N, Lingam Ragavi R et al.

ROTASIIL®, a pentavalent oral rotavirus vaccine licensed in India in 2017, was introduced into the Universal Immunization Program in 2018. Primary endpoint was vaccine effectiveness (VE) against moderate and severe rotavirus gastroenteritis (RVGE) in children <2 years using pooled data from two multi-center observational studies across 32 hospitals in seven states (July 2019-December 2023). A test-negative case-control design estimated adjusted VE (aVE) for three ROTASIIL® doses. Among 2,243 children aged 3-23 months hospitalized with acute gastroenteritis, 638 were ELISA-positive. For completed series (three doses), the aVE against hospitalization due to RVGE among children aged 3-23 months was 52% (95% CI, 32-66), with the highest aVE of 88% (CI, 53-97) observed among those aged 3-5 months. The aVE against moderate RVGE was 56% (CI, 11-79), and that of severe RVGE was 54% (CI, 31-70). The highest genotype-specific aVE was 62% (CI, 29-80) against G1P[8]. For at least one dose, the aVE was 45% (CI, 26-60) among children aged 1-23 months. A completed series of ROTASIIL® effectively reduced RVGE hospitalizations especially with a higher VE observed in younger age groups, suggesting the benefits of timely immunization.

PMID 42881148
Read full article →
PubMedInternational journal of molecular sciences2026-10-16

Immune Profiles Elicited by Different HBV Vaccine Modalities and Their Associations with Serological and Intrahepatic Viral Outcomes.

Xiao Huiying H, He Jinhang J, Zhu Lili L, Wang Songmei S et al.

Therapeutic vaccination for chronic hepatitis B aims to restore HBV-specific T-cell immunity and contribute to a functional cure. We systematically compared the immune profiles and antiviral efficacy of four vaccine modalities: recombinant HBsAg (rHBsAg), antigen-antibody immune complex (IC), a DNA vaccine encoding HBsAg (DNA-HBsAg), and an HBsAg-Fc fusion DNA vaccine (DNA-HBsAg-Fc). In naïve mice, the rHBsAg vaccine predominantly induced anti-HBs IgG responses, whereas the IC vaccine elicited strong anti-HBs IgG and detectable CD4+ T-cell responses. In contrast, DNA vaccines preferentially induced HBsAg-specific CD8+ T-cell immunity, which was further enhanced by fusion to the Fc fragment of human IgG1. In the pre-immunization/AAV-HBV model, high anti-HBs titers in rHBsAg and IC groups were associated with rapid clearance of circulating HBsAg but not with comparable reductions in HBcAg+ hepatocytes, whereas stronger HBsAg-specific CD8+ T-cell responses in the DNA vaccine groups were associated with greater reductions in HBcAg+ hepatocytes. However, in the therapeutic AAV-HBV model, all vaccine monotherapies showed limited and non-sustained antiviral efficacy, with only transient reductions in serum HBsAg and limited reductions in HBcAg+ hepatocytes. These findings highlight the distinct immune profiles of different vaccine platforms and an association between stronger HBsAg-specific CD8+ T-cell responses and reduced intrahepatic HBcAg expression, while underscoring the limited efficacy of vaccine monotherapy in the AAV-HBV model.

PMID 42883747
Read full article →
PubMedMilitary medicine2026-10-16

The Case for Dedicated Vaccine Communication Training: A Survey of Military Pediatricians.

Auvil Daley D, Jones Katherine K, Ratusnik Rebecca R, Adams Daniel J DJ

Vaccine uncertainty is rising among families in the United States, even among military families. The ACGME mandates that pediatric residents be trained in effective communication strategies for patients and families hesitant about recommended vaccinations, yet few validated curriculum tools exist. We aimed to understand the current landscape of vaccine uncertainty experienced by military general pediatricians and see what communication strategies were routinely being implemented in clinical practice. In March 2025, 45 graduates of a mid-sized military pediatrics residency program from the years 2016-2024 who were currently practicing general pediatricians were invited to participate in a survey on vaccine communication in clinical practice. The survey was a mix of quantitative questions asking for experienced trends in vaccine uncertainty as well as open-ended questions about communication strategies being implemented. Three clinical researchers performed a manual thematic analysis of free-text answers to understand and quantify common themes. Thirty-seven general pediatricians (82%) responded, and 95% of those surveyed rated a curriculum during medical training on vaccine communication as "very" or "extremely important." Only 19% of physicians were able to recall formal training in addressing vaccine hesitancy during medical school, and only 62% during residency. The 3 most commonly declined vaccines were COVID-19, influenza, and HPV. Pediatricians reported using communication strategies focused on knowledge-sharing (65%), partnership with families (62%), and normalizing vaccines (40%). Common barriers to vaccine acceptance were mistrust and disinterest, most commonly with unwillingness to engage in a conversation. Most practicing military pediatricians who graduated from our residency program report a rise in vaccine uncertainty in their practice and agree that a residency curriculum on vaccine communication is highly important. Such curricula should encourage evidence-based communication styles using vaccine normalization while de-emphasizing the urge to combat misinformation using knowledge-sharing and should specifically address the most commonly declined immunizations.

PMID 42885154
Read full article →
PubMedAnnals of Indian Academy of Neurology2026-10-16

Neurological Manifestations in People Living with Human Immunodeficiency Virus (PLHIV) in India: A Scoping Review and the Need for a National HIV-Neurology Special Interest Group.

Mustafa Farsana F, Garg Divyani D, Vishnu Venugopalan Y VY, Srivastava Achal Kumar AK et al.

Despite a low national prevalence of 0.20%, India's absolute burden of 2.544 million people living with human immunodeficiency virus (HIV) presents clinicians with varied neurological complications. While combination antiretroviral therapy (ART) has extended survival, the neuro-HIV profile in India, characterized by the predominance of HIV-1 clade C, remains distinct from that reported in Western cohorts. This scoping review aimed to identify patterns of neurological manifestations in India across the pre-ART, ART, and "treat-all" eras and to support the establishment of a National HIV Neurology Special Interest Group. Following Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines, a systematic search was conducted for studies published between 1991 and 2025. Eligible studies included Indian adults living with HIV aged ≥18 years with definitive neurological syndromic diagnoses. A total of 148 studies involving 3,433 patients were included. The "treat-all" era (post-2017) had the highest reporting volume from India. The central nervous system involvement predominated (94.7%), with opportunistic infections identified as the most common etiology (74.83%). Meningitis was the most-frequent neurological syndrome (1,187 cases; 54.5%), and Cryptococcus (439 cases; 12.78%) and Mycobacterium tuberculosis (374 cases; 10.89%) were the most common pathogens. Diagnoses were commonly established using a combination of clinical examination, neuroimaging, and cerebrospinal fluid analysis (2,799 cases; 81.5%). ART data were unavailable for 91.8% of patients. The neurology-HIV scenario in India is characterized by a high burden of acute opportunistic infections. The significant dependence on empirical polypharmacy and the identified gaps in ART-related data reveal a poorly integrated care model.

PMID 42885970
Read full article →
PubMedNature communications2026-10-16

Klebsiella-dominant gut communities are associated with impeded oral rotavirus vaccine response in infants.

Seymour Cale O CO, Ecklu-Mensah Gertrude G, Lee Yesun Y, Nicols Alexander R AR et al.

Rotavirus gastroenteritis is the leading cause of infant diarrheal death worldwide. Oral rotavirus vaccine (RVV) prevents illness and death, but efficacy differs between high- and low-income countries and the etiologies are unclear. Here, we describe the relationship between colonization of the infant gut by commensal bacteria, inflammation, and vaccine response across a cohort of infants from Panama, Peru, and the U.S. Vaccine immunogenicity was related to community composition in the first month of life and inverse to increased relative abundance of Klebsiella. Clustering communities into gut types revealed that microbiome configurations with elevated Klebsiella or Escherichia in the first month of life were negatively associated with both seroconversion and rotavirus shedding after vaccination, suggesting potential inhibition of vaccine function or host response. Infants without RVV strain shedding displayed elevated fecal calprotectin in the first month. These results implicate microbiome-augmented infant gut inflammation as a potential impediment to RVV response.

PMID 42881193
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about measles